Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Group A streptococcal vaccines.

J B Dale1

  • 1Division of Infectious Diseases, University of Tennessee, Memphis, USA.

Infectious Disease Clinics of North America
|April 13, 1999
PubMed
Summary
This summary is machine-generated.

This review covers group A streptococcal infection pathogenesis and antigens for vaccines. Preclinical data show M protein vaccines protect animals, guiding future broadly protective vaccine strategies against infections and rheumatic fever.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum for Barth et al., "Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town".

mSphere·2019
Same author

Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town.

mSphere·2019
Same author

Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2009
Same author

Hormonal regulation of androgen receptor messenger ribonucleic acid expression in human tooth pulp.

Journal of dental research·2002
Same author

Spa contributes to the virulence of type 18 group A streptococci.

Infection and immunity·2001
Same author

Identification of a gene within a pathogenicity island of enterotoxigenic Escherichia coli H10407 required for maximal secretion of the heat-labile enterotoxin.

Infection and immunity·2000
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Area of Science:

  • Microbiology and Immunology
  • Vaccine Development
  • Infectious Diseases

Background:

  • Group A Streptococcus (GAS) causes significant human infections.
  • Understanding GAS pathogenesis and immune response antigens is crucial for effective vaccines.
  • Acute rheumatic fever remains a major global health concern linked to GAS.

Purpose of the Study:

  • To review the pathogenesis of group A streptococcal infections.
  • To identify antigens involved in protective immune responses.
  • To discuss current and future vaccine development strategies for GAS.

Main Methods:

  • Literature review of pathogenesis and immunology of GAS infections.
  • Analysis of preclinical data from M protein-based vaccine studies.

Related Experiment Videos

  • Discussion of emerging vaccine technologies and strategies.

    • Main Results:

    • Preclinical studies demonstrate multivalent M protein-based vaccines induce protective antibodies in animals.
    • M protein is a key target antigen for GAS vaccine development.
    • Various vaccine approaches are under investigation.

    Conclusions:

    • M protein-based vaccines show promise for preventing GAS infections.
    • Future strategies aim for broadly protective vaccines against diverse GAS strains.
    • Successful vaccines could significantly reduce GAS disease and acute rheumatic fever incidence.